ADIPOQ and metabolic dysfunction-associated steatohepatitis: It has been suggested that adiponectin may play an important role in mediating the beneficial effects of pioglitazone in NASH patients, inhibiting hepatic fatty acid synthesis, gluconeogenesis and de novo lipogenesis, via activation of AMPK.